These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 9620627)
1. A novel areneisonitrile Tc complex inhibits the transport activity of MDR P-glycoprotein. Rao VV; Herman LW; Kronauge JF; Piwnica-Worms D Nucl Med Biol; 1998 Apr; 25(3):225-32. PubMed ID: 9620627 [TBL] [Abstract][Full Text] [Related]
2. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Piwnica-Worms D; Chiu ML; Budding M; Kronauge JF; Kramer RA; Croop JM Cancer Res; 1993 Mar; 53(5):977-84. PubMed ID: 8094997 [TBL] [Abstract][Full Text] [Related]
3. Characterization of multidrug resistance P-glycoprotein transport function with an organotechnetium cation. Piwnica-Worms D; Rao VV; Kronauge JF; Croop JM Biochemistry; 1995 Sep; 34(38):12210-20. PubMed ID: 7547962 [TBL] [Abstract][Full Text] [Related]
4. Novel hexakis(areneisonitrile)technetium(I) complexes as radioligands targeted to the multidrug resistance P-glycoprotein. Herman LW; Sharma V; Kronauge JF; Barbarics E; Herman LA; Piwnica-Worms D J Med Chem; 1995 Jul; 38(15):2955-63. PubMed ID: 7636856 [TBL] [Abstract][Full Text] [Related]
5. Assessment of the in vitro and in vivo properties of a (99m)Tc-labeled inhibitor of the multidrug resistant gene product P-glycoprotein. Bergmann R; Brust P; Scheunemann M; Pietzsch HJ; Seifert S; Roux F; Johannsen B Nucl Med Biol; 2000 Feb; 27(2):135-41. PubMed ID: 10773542 [TBL] [Abstract][Full Text] [Related]
7. Characterization of a novel 99mTc-carbonyl complex as a functional probe of MDR1 P-glycoprotein transport activity. Dyszlewski M; Blake HM; Dahlheimer JL; Pica CM; Piwnica-Worms D Mol Imaging; 2002; 1(1):24-35. PubMed ID: 12920858 [TBL] [Abstract][Full Text] [Related]
8. Involvement of glutathione in loss of technetium-99m-MIBI accumulation related to membrane MDR protein expression in tumor cells. Moretti JL; Duran Cordobes M; Starzec A; de Beco V; Vergote J; Benazzouz F; Boissier B; Cohen H; Safi N; Piperno-Neumann S; Kouyoumdjian JC J Nucl Med; 1998 Jul; 39(7):1214-8. PubMed ID: 9669397 [TBL] [Abstract][Full Text] [Related]
9. In vivo and in vitro multitracer analyses of P-glycoprotein expression-related multidrug resistance. Márián T; Szabó G; Goda K; Nagy H; Szincsák N; Juhász I; Galuska L; Balkay L; Mikecz P; Trón L; Krasznai Z Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1147-54. PubMed ID: 12830325 [TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein versus MRP1 on transport kinetics of cationic lipophilic substrates: a comparative study using [99mTc]sestamibi and [99mTc]tetrofosmin. Gomes CM; Abrunhosa AJ; Pauwels EK; Botelho MF Cancer Biother Radiopharm; 2009 Apr; 24(2):215-27. PubMed ID: 19409044 [TBL] [Abstract][Full Text] [Related]
11. Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin. Chen WS; Luker KE; Dahlheimer JL; Pica CM; Luker GD; Piwnica-Worms D Biochem Pharmacol; 2000 Aug; 60(3):413-26. PubMed ID: 10856437 [TBL] [Abstract][Full Text] [Related]
12. Imaging multidrug resistance P-glycoprotein transport function using microPET with technetium-94m-sestamibi. Bigott HM; Prior JL; Piwnica-Worms DR; Welch MJ Mol Imaging; 2005; 4(1):30-9. PubMed ID: 15967124 [TBL] [Abstract][Full Text] [Related]
13. A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors. Kelly RJ; Robey RW; Chen CC; Draper D; Luchenko V; Barnett D; Oldham RK; Caluag Z; Frye AR; Steinberg SM; Fojo T; Bates SE Oncologist; 2012; 17(4):512. PubMed ID: 22416063 [TBL] [Abstract][Full Text] [Related]
14. Differential effects of toremifene on doxorubicin, vinblastine and Tc-99m-sestamibi in P-glycoprotein-expressing breast and head and neck cancer cell lines. Mubashar M; Harrington KJ; Chaudhary KS; Lalani el-N; Stamp GW; Peters AM Acta Oncol; 2004; 43(5):443-52. PubMed ID: 15360048 [TBL] [Abstract][Full Text] [Related]
15. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. Vecchio SD; Ciarmiello A; Potena MI; Carriero MV; Mainolfi C; Botti G; Thomas R; Cerra M; D'Aiuto G; Tsuruo T; Salvatore M Eur J Nucl Med; 1997 Feb; 24(2):150-9. PubMed ID: 9021112 [TBL] [Abstract][Full Text] [Related]
16. 99mTc-Sestamibi, a sensitive probe for in vivo imaging of P-glycoprotein inhibition by modulators and mdr1 antisense oligodeoxynucleotides. Jekerle V; Wang JH; Scollard DA; Reilly RM; Wiese M; Piquette-Miller M Mol Imaging Biol; 2006; 8(6):333-9. PubMed ID: 16955376 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the accumulation and efflux kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line. Utsunomiya K; Ballinger JR; Piquette-Miller M; Rauth AM; Tang W; Su ZF; Ichise M Eur J Nucl Med; 2000 Dec; 27(12):1786-92. PubMed ID: 11189941 [TBL] [Abstract][Full Text] [Related]
18. TC-99m MIBI SPECT imaging in patients with lung carcinoma: is it a functional probe of multidrug resistance genes? Ak I; Gülbaş Z; Ocak S; Kaya E; Alataş F; Vardareli E; Metintaş M J Comput Assist Tomogr; 2007; 31(5):795-9. PubMed ID: 17895794 [TBL] [Abstract][Full Text] [Related]
19. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128 [TBL] [Abstract][Full Text] [Related]
20. 99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer. Mubashar M; Harrington KJ; Chaudhary KS; Lalani el-N; Stamp GW; Sinnett D; Glass DM; Peters AM J Nucl Med; 2002 Apr; 43(4):519-25. PubMed ID: 11937596 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]